Delving into the Latest Updates on LG-190119 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Target-

Action-

Mechanism-

Therapeutic Areas

NeoplasmsUrogenital Diseases

Active Indication-

Inactive Indication

Prostatic Cancer

Originator Organization

Baylor College of Medicine

Active Organization-

Inactive Organization

Baylor College of Medicine

License Organization-

Drug Highest PhasePendingDiscovery

First Approval Date-

Regulation-

AbstractBackgroundWe recently reported on novel vitamin D receptor (VDR) modulators that are structurally distinct from the secosteroid 1,25‐dihydroxyvitamin D3 (1,25(OH)2D3), the endogenous activator of VDR. One of these compounds, LG190119, was tested for the ability to inhibit the growth of LNCaP human prostate cancer cell‐derived tumors in athymic mice.MethodsIn one study, athymic mice with established LNCaP xenograft tumors were dosed orally every day with LG190119 (3 or 10 mg/kg) or with a synthetic analog of 1,25(OH)2D3, EB1089 (1 μg/kg), for 15 days. In another study (“prevention mode”), oral administration (every other day) of 10 mg/kg LG190119 or a non‐hypercalcemic dose of 1,25(OH)2D3 (0.5 μg/kg) was initiated prior to tumor development and continued for 84 days. In both studies, tumor volumes, mouse weights, and serum calcium levels were measured.ResultsIn the established tumor study, LG190119 at each dose resulted in significant tumor growth inhibition without hypercalcemia at both 10 and 15 days. EB1089 treatment resulted in significant tumor growth inhibition only at Day 10 and resulted in hypercalcemia at Day 15. In the prevention‐mode study, LG190119 markedly slowed tumor growth without increased serum calcium in comparison with either vehicle or 1,25(OH)2D3 treatment (P < 0.001).ConclusionsLG190119 effectively inhibited LNCaP xenograft tumor growth without increased serum calcium levels or any other apparent side effects. Compounds of this class may represent promising new therapeutics for treatment of prostate cancer and other cancers with fewer undesirable side effects than currently used drugs. Prostate 49:224–233, 2001. © 2001 Wiley‐Liss, Inc.

100 Deals associated with LG-190119

Login to view more data